Clinical Trials Logo

Filter by:
  • Withdrawn  
  • « Prev · Page [4]
NCT ID: NCT00349518 Withdrawn - Clinical trials for Acute Lymphoblastic Leukemia

Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL

Start date: December 2006
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to further assess the safety of dasatinib in imatinib intolerant or resistant patients with chronic phase chronic myeloid leukemia, advanced phase chronic myeloid leukemia or Philadelphia chromosome positive acute lymphoblastic leukemia. The efficacy of the drug in this kind of patients will also further be documented.

NCT ID: NCT00112060 Withdrawn - Clinical trials for Non-Small-Cell Lung Carcinoma

A Study to Assess the Safety and Preliminary Efficacy of PT-523 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Start date: April 2008
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II, multi-centered, non-randomized trial is designed to determine a safe dose of PT-523 for subjects, and to make preliminary evaluations on the activity of PT-523 as therapy in subjects with NSCLC.

NCT ID: NCT00104143 Withdrawn - Multiple Sclerosis Clinical Trials

A Study of A4I Antagonist in Patients With Relapsing Multiple Sclerosis.

Start date: October 2007
Phase: Phase 2
Study type: Interventional

This study will compare the effect of A4I antagonist and placebo on MRI lesions,on clinical endpoints, and safety in patients with relapsing Multiple Sclerosis (MS). Eligible patients will be randomized to receive placebo or A4I antagonist, 20mg, 80mg or 300mg, po bid. Patients will undergo MRI brain scans and MS clinical evaluations at intervals throughout the study. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.